Clotrimazole Treatment of Oral Candidiasis in Patients With Neoplastic Disease

Shechtman, Liran; Funaro, L.; Robin, Tyler P.; Bottone, Edward J.; Cuttner, Janet

doi:10.1016/s0022-5347(17)50884-8

Cited by 4 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Study Year Country Total No. eligible patients Mean age (years) Diagnosis of OC Clotrimazole Control Formulation Dose (mg) Frequency (times/day) Duration (days) Medication Formulation Dose (mg) Frequency (times/day) Duration (days) ( Montes et al, 1976 ) 1976 USA 12 32 C + M Troches 10 10 14 Clotrimazole Troches 50 10 14 ( Kirkpatrick & Alling, 1978 ) 1978 USA 20 26 C + M Troches 10 5 14 Placebo Troches – 5 14 ( Yap & Bodey, 1979 ) 1979 USA 48 (52 episodes) 44 C + M Troches 10 5 14 Clotrimazole Troches 50 5 14 ( Lawson & Bodey, 1980 ) 1980 USA 84 (88 episodes) 43 C + M Troches 50 5 14 Nystatin Vaginal tablet – 5 14 ( Shechtman et al, 1984 ) 1984 USA 16 – C + M...…”

Section: Resultsmentioning

confidence: 99%

“…of clinical responses/Total evaluable patients) % Mycological cure b (No. of mycological cures/Total evaluable patients) Clotrimazole Control P-value Clotrimazole Control P-value ( Montes et al, 1976 ) Non-specific Clotrimazole 50 mg 100 (6/6) 100 (6/6) NS 50 (3/6) 50 (3/6) NS ( Kirkpatrick & Alling, 1978 ) Non-specific Placebo 100 (10/10) 10 (1/10) P < 0.001 90 (9/10) 10 (1/10) – ( Yap & Bodey, 1979 ) c Cancer Clotrimazole 50 mg 96 (25/26) 96 (25/26) – 34 (9/26) 69 (18/26) – ( Lawson & Bodey, 1980 ) c Cancer Nystatin 94 (34/36) 100 (30/30) – 56 (20/36) 47 (14/30) – ( Shechtman et al, 1984 ) Cancer Placebo 86 (6/7) 17 (1/6) P = 0.025 43 (3/7) 0 (0/6) P = 0.12 ( Thamlikitkul et al, 1988 ) Non-specific Ketoconazole 100 100 – 64 64 – ( Koletar et al, 1990 ) HIV Fluconazole 65 (11/17) 100 (16/16) P = 0.018 20 (3/15) 75 (12/16) P = 0.004 ( Conrad & Lentnek, 1990 ...…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of clotrimazole for the management of oral candidiasis: A meta-analysis of randomized clinical trials

Almangour

Kaye

Alessa

et al. 2021

Saudi Pharmaceutical Journal

View full text Add to dashboard Cite

Purpose To assess the efficacy and safety of topical application of clotrimazole versus others in the treatment of oropharyngeal candidiasis (OPC). Method Four electronic databases, registries of ongoing trials, and manual search were used to identify randomized controlled trials (RCTs) that compared the efficacy of clotrimazole to other antifungal agents in patients who were clinically diagnosed with oral candidiasis up to November 1st, 2019. Primary outcomes were clinical response and mycological cure rates. Secondary outcomes include relapse rate, incidence of systemic infections, and compliance. Adverse effects were also evaluated. Results Sixteen RCTs with a total of 1685 patients were included. Half of the eligible studies were considered at high risk of performance bias and more than a third, at high risk of reporting bias. Our analysis showed no significant difference in clinical response between clotrimazole and all other antifungal agents. However, clotrimazole was less effective in terms of mycologic cure and relapse rate. Sensitivity analysis comparing clotrimazole to other topical antifungal agents only showed no differences in clinical response, microbiologic cure or relapse. Further sensitivity analysis showed significant efficacy of fluconazole over clotrimazole. Conclusion This meta-analysis indicated that clotrimazole is less effective than fluconazole but as effective as other topical therapies in treating OPC. Well-designed high-quality RCT is needed to validate these findings.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Efficacy of clotrimazole for the management of oral candidiasis: A meta-analysis of randomized clinical trials

Almangour

Kaye

Alessa

et al. 2021

Saudi Pharmaceutical Journal

View full text Add to dashboard Cite

show abstract

“…Generally, a smear is of value for differentiating between yeast and hyphal forms, but it is less sensitive than cultural methods 6 . According to a survey of the colonisation of Candida in 67 patients with malignant diseases, 11 patients showed positive findings in both smears and cultures for Candida , and an additional 26 patients had positive findings only on cultures for Candida 17 .…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Fungiflora Y staining for the diagnosis of oral erythematous candidiasis

et al. 2012

View full text Add to dashboard Cite

show abstract

“…It is the most common fungal infection in patients with HIV infection, perhaps reflecting Candida’s niche as a component of the endogenous flora of the human alimentary tract. Conditions due to Candida species include, but are not limited to, oropharyngeal candidiasis 8 – 10 esophageal candidiasis 11 , gastrointestinal candidiasis 12 13 , hematogenous Candida endophathalmitis 14 15 , hepatosplenic candidiasis 16 , renal candidiasis 17 , Candida cystitis 18 , epiglottitis 19 , Peritonitis 20 , cholecystitis 21 , prosthetic valve endocarditis 22 , vascular catheter- associated fungemia and thrombophlebitis 23 24 . Many infections due to C andida species are refractory to antifungal therapy.…”

Section: Fungal Infectionsmentioning

confidence: 99%

Antifungals: Need to search for a new molecular target

Sangamwar¹,

Deshpande

Pekamwar³

2008

Indian J Pharm Sci

View full text Add to dashboard Cite

In the 1990s, drug resistance has become an important problem in a variety of infectious diseases including human immunodeficiency virus infection, tuberculosis, and other bacterial infections which have profound effects on human health. At the same time, there have been dramatic increase in the incidence of fungal infections, which are probably the result of alterations in immune status associated with the acquired immuno deficiency syndrome epidemic, cancer chemotherapy, and organ and bone marrow transplantation. The rise in the incidence of fungal infections has exacerbated the need for the next generation of antifungal agents, since many of the currently available drugs have undesirable side effects, are ineffective against new or reemerging fungi, or lead to the rapid development of the resistance. This review will focus on the pathogenic yeast Candida albicans, since a large body of work on the factors and mechanism associated with antifungal drug resistance in this organism is reported sufficiently. It will certainly elaborate the probable molecular targets for drug design, discovered to date.

show abstract

Clotrimazole Treatment of Oral Candidiasis in Patients With Neoplastic Disease

Cited by 4 publications

References 0 publications

Efficacy of clotrimazole for the management of oral candidiasis: A meta-analysis of randomized clinical trials

Efficacy of clotrimazole for the management of oral candidiasis: A meta-analysis of randomized clinical trials

Efficacy of Fungiflora Y staining for the diagnosis of oral erythematous candidiasis

Antifungals: Need to search for a new molecular target

Contact Info

Product

Resources

About